Fangzhou faces challenges with decreasing drug price due to VBP/NRDL negotiation. The internal disputes, litigation, cash flow pressure will lead to uncertain growth prospects/performance stability.
What is covered in the Full Insight:
Fangzhou's Business Model
Revenue Breakdown
Challenges and Issues
Performance Comparison with Competitors
Fangzhou's Valuation
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.